Brown Kenneth, Scott-Hoy Brandi, Jennings Linda W
Kenneth Brown, Brandi Scott-Hoy, KBS Research LLC, Dallas, TX 75248, United States.
World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):463-8. doi: 10.4292/wjgpt.v7.i3.463.
The aim of this case series was to retrospectively examine the symptom response of irritable bowel syndrome with constipation (IBS-C) patients administered an herbal extract in a real-world setting. Twenty-four IBS-C patients in a community office practice were provided a combination over-the-counter dietary supplement composed of quebracho (150 mg), conker tree (470 mg) and M. balsamea Willd (0.2 mL) extracts (Atrantil™) and chose to take the formulation for a minimum of 2 wk in an attempt to manage their symptoms. Patient responses to the supplement were assessed by visual analogue scale (VAS) for abdominal pain, constipation and bloating at baseline and at 2 wk as part of standard-of-care. Patient scores from VAS assessments recorded in medical chart data were retrospectively compiled and assessed for the effects of the combined extract on symptoms. Sign tests were used to compare changes from baseline to 2 wk of taking the extract. Significance was defined as P < 0.05. Twenty-one of 24 patients (88%) responded to the dietary supplement as measured by individual improvements in VAS scores for abdominal pain, bloating and constipation symptoms comparing scores prior to administration of the extract against those reported after 2 wk. There were also significant improvements in individual as well as mean VAS scores after 2 wk of administration of the combined extract compared to baseline for abdominal pain [8.0 (6.5, 9.0) vs 2.0 (1.0, 3.0), P < 0.001], bloating [8.0 (7.0, 9.0) vs 1.0 (1.0, 2.0), P < 0.001] and constipation [6.0 (3.0, 8.0) vs 2.0 (1.0, 3.0), P < 0.001], respectively. In addition, 21 of 24 patients expressed improved quality of life while taking the formulation. There were no reported side effects to administration of the dietary supplement in this practice population suggesting excellent tolerance of the formulation. This pilot retrospective analysis of symptom scores from patients before and after consuming a quebracho/conker tree/M. balsamea Willd extract may support the formulation's use in IBS-C.
本病例系列的目的是在实际应用环境中,对接受草药提取物治疗的便秘型肠易激综合征(IBS-C)患者的症状反应进行回顾性研究。社区诊所的24名IBS-C患者服用了一种非处方膳食补充剂组合,其成分包括破斧树提取物(150毫克)、七叶树提取物(470毫克)和香脂月桂提取物(0.2毫升)(Atrantil™),并选择服用该制剂至少2周以缓解症状。作为标准护理的一部分,通过视觉模拟量表(VAS)在基线和2周时评估患者对该补充剂的反应,评估指标包括腹痛、便秘和腹胀。回顾性收集病历数据中记录的VAS评估患者得分,并评估复合提取物对症状的影响。采用符号检验比较服用提取物从基线到2周的变化。显著性定义为P<0.05。与服用提取物前相比,24名患者中有21名(88%)在服用2周后,VAS评分中腹痛、腹胀和便秘症状均有改善。与基线相比,服用复合提取物2周后,个体以及平均VAS评分在腹痛[8.0(6.5,9.0)对2.0(1.0,3.0),P<0.001]、腹胀[8.0(7.0,9.0)对1.0(1.0,2.0),P<0.001]和便秘[6.0(3.0,8.0)对2.0(1.0,3.0),P<0.001]方面也有显著改善。此外,24名患者中有21名在服用该制剂时表示生活质量有所改善。在该实际应用人群中,未报告服用膳食补充剂的副作用,表明该制剂耐受性良好。这项对服用破斧树/七叶树/香脂月桂提取物前后患者症状评分的初步回顾性分析,可能支持该制剂在IBS-C中的应用。